A prospective oBservatIonal sTUdy of patients with metastatic castration resistant prostate cancer progressing after stanDard hormonal therapy suitable for abiraterone acetate trEatment - ABItude
Project objectives
Prospective multicenter observational study involving patients with castration-resistant metastatic prostate cancer in progression after hormone therapy standards eligible for treatment with abiraterone acetate. This study aims to evaluate the effectiveness of abiraterone acetate in normal clinical practice in terms of PSA reduction, disease-free radiographic survival and duration of clinical benefit.
Start/End Date
18/05/2016, ongoing
Project manager
Dott. Fiore Michele
Coordinator of the project
Medical Oncology, National Cancer Institute Milan
Sources of financing
Janssen-Cilag SPA